Category:

New Safety Data on treatment with COPAXONE® (glatiramer acetate) of Breastfeeding Mothers who Live with Relapsing Multiple Sclerosis: COBRA study presented at the 7th Congress of the European Academy of Neurology (EAN) – Business Wire

CONTEXT:  Presentation of a non-interventional study on breastfeeding mothers with Relapsing Multiple Sclerosis (MS) taking Copaxone at the 7th annual congress of the European Academy of Neurology (EAN).  Around a Continue Reading

Posted On : Published By : Ken Ashman
Category:

Teva Presents New Data at 7th European Academy of Neurology Congress Suggesting Socio-Economic Factors May Contribute to the Significant Under-Diagnosis of Migraine – Business Wire

CONTEXT:  Presentation of a retrospective study in migraine epidemiology in Southern Israel at the 7th Congress of the European Academy of Neurology (EAN).  Findings showed extreme variability in the prevalence Continue Reading

Posted On : Published By : Ken Ashman
Category:

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection Presented at 2021 American Headache Society (AHS) Annual Meeting – Business Wire

CONTEXT:  Continuing this years theme of presenting RWR posters alongside traditional RCTs, Teva showed off their AJOVY (fremanezumab-vfrm) treatment for migraine at the American Headache Society annual meeting.  Also included Continue Reading

Posted On : Published By : Ken Ashman
Category:

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting – Business Wire

CONTEXT:  It seems that having Real-World Data (capitalised for emphasis) alongside your traditional clinical data at a poster presentation now adds weight to the overall message.  RWR is the must-have Continue Reading

Posted On : Published By : Ken Ashman